Evolving Treatments for Advanced Renal Cell Carcinoma: ASCO 2023 and Beyond - Episode 17

Future Perspectives in the Treatment of Advanced RCC

,

Oncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.

EP. 1: Overview of First-Line Combination Therapy in Advanced Clear Cell RCC
EP. 2: Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC
EP. 3: Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
EP. 4: Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC
EP. 5: Selecting Therapy for a Real-World Patient With Clear Cell RCC
EP. 6: Rationale Behind Discontinuing IO Therapy in Clear Cell RCC
EP. 7: Second-Line Treatment Armamentarium in Clear Cell RCC
EP. 8: Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies
EP. 9: Selecting Optimal Therapy for Advanced Non-Clear Cell RCC
EP. 10: Renal Cell Carcinoma: Future Evolutions in Care
EP. 11: Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)
EP. 12: Available Treatment Options for Patients with Advanced RCC
EP. 13: Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC
EP. 14: Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCC
EP. 15: Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC
EP. 16: Key Takeaways in the Treatment of Advanced RCC From KCRS 2023
Now Viewing
EP. 17: Future Perspectives in the Treatment of Advanced RCC